Search research articles
Contact Us
Filters
Showing results (11-20 of 50) with videos related to
Page
of 5
Sort By:
Journal of Travel Medicine
|
August 29, 2020
What will travel medicine look like in the COVID-19 pandemic era?
David R Shlim, Bradley A Connor, David N Taylor
Journal of Pediatric Gastroenterology and Nutrition
|
October 24, 2002
Growth slowing after acute Helicobacter pylori infection is age-dependent
Douglas J Passaro, David N Taylor, Robert H Gilman, et al.
Antimicrobial Agents and Chemotherapy
|
December 19, 2007
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis
David N Taylor, Robin McKenzie, Anna Durbin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 6, 2006
Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge
David N Taylor, Robin McKenzie, Anna Durbin, et al.
Vaccine
|
January 22, 2008
Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel
Darrell E Singer, Rachel Schneerson, Christian T Bautista, et al.
Viruses
|
September 23, 2022
The Rise and Fall of SARS-CoV-2 Variants and Ongoing Diversification of Omicron
Tanner Wiegand, Artem Nemudryi, Anna Nemudraia, et al.
Journal of Travel Medicine
|
January 24, 2007
Rifaximin treatment of pathogen-negative travelers' diarrhea
Herbert L DuPont, Robert Haake, David N Taylor, et al.
The Journal of Pediatrics
|
February 28, 2002
Effects of nutritional status on diarrhea in Peruvian children
William Checkley, Robert H Gilman, Robert E Black, et al.
Vaccine
|
May 21, 2011
Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI)
David N Taylor, John J Treanor, Cynthia Strout, et al.
Vaccine
|
June 27, 2006
Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial
Geoffrey J Gorse, Wendy Keitel, Harry Keyserling, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 50) with videos related to
Sort By:
Page
of 5
Journal of Travel Medicine
|
August 29, 2020
What will travel medicine look like in the COVID-19 pandemic era?
David R Shlim, Bradley A Connor, David N Taylor
Journal of Pediatric Gastroenterology and Nutrition
|
October 24, 2002
Growth slowing after acute Helicobacter pylori infection is age-dependent
Douglas J Passaro, David N Taylor, Robert H Gilman, et al.
Antimicrobial Agents and Chemotherapy
|
December 19, 2007
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis
David N Taylor, Robin McKenzie, Anna Durbin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 6, 2006
Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge
David N Taylor, Robin McKenzie, Anna Durbin, et al.
Vaccine
|
January 22, 2008
Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel
Darrell E Singer, Rachel Schneerson, Christian T Bautista, et al.
Viruses
|
September 23, 2022
The Rise and Fall of SARS-CoV-2 Variants and Ongoing Diversification of Omicron
Tanner Wiegand, Artem Nemudryi, Anna Nemudraia, et al.
Journal of Travel Medicine
|
January 24, 2007
Rifaximin treatment of pathogen-negative travelers' diarrhea
Herbert L DuPont, Robert Haake, David N Taylor, et al.
The Journal of Pediatrics
|
February 28, 2002
Effects of nutritional status on diarrhea in Peruvian children
William Checkley, Robert H Gilman, Robert E Black, et al.
Vaccine
|
May 21, 2011
Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI)
David N Taylor, John J Treanor, Cynthia Strout, et al.
Vaccine
|
June 27, 2006
Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial
Geoffrey J Gorse, Wendy Keitel, Harry Keyserling, et al.
Page
of 5